Pharma ETFs Gain Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Sector ETF report for XPH
ETFs to Buy on Solid Q1 JNJ Earnings Results
Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Smart Beta ETF report for PJP
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
Sector ETF report for PJP
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Sector ETF report for IHE
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Smart Beta ETF report for XPH
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Sector ETF report for PPH
A Look at Pharma ETFs Post Q4 Earnings
Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.